Case Summary: Right Ureteric Calculus with Hydroureteronephrosis

Clinical Picture

• Chief complaints: Right loin pain radiating to the groin, with abdominal bloating.
• History: Sudden onset severe colicky right flank pain, worsening with/during micturition, accompanied by fever and hematuria - the classic triad for a ureteric stone causing obstruction and secondary infection.
• Vitals on admission: PR 90/min, BP 120/80, Temp 98.7°F, SpO2 97% RA, RR 16/min - hemodynamically stable, low-grade or resolving fever.
• Systemic exam: CVS/RS/CNS unremarkable, abdomen soft (no peritonism) - consistent with uncomplicated renal colic rather than an acute surgical abdomen.
• Serial vitals (days 13-15) show stable trends (BP ranging 110-130/70-80, HR 69-70, SpO2 97-99%), indicating the patient responded well to treatment without sepsis or hemodynamic compromise.

Diagnosis

• CT/USG (KUB): Right moderate hydronephrosis and ureterosis (proximal dilatation) secondary to a lower (distal) ureteric calculus - i.e., a stone lodged in the lower ureter is obstructing urine flow, backing up into the kidney (hydronephrosis) and ureter (hydroureter).
• Chest X-ray and ECG were done as routine pre-anesthetic/pre-procedure work-up and were reported normal (NSR on ECG).

Inpatient Treatment (Stat orders + Treatment chart, 14/7-16/7)

Discharge Medications (7 days)

Why these drug choices make sense together

• Antibiotics (cephalosporin-sulbactam + aminoglycoside inpatient, then Augmentin outpatient) treat the associated infection/fever from the obstructed, stagnant urine.
• Tamsulosin-based MET is well supported for distal ureteric stones - it improves spontaneous stone passage rates and reduces colic episodes. Recent systematic reviews/meta-analyses continue to support alpha-blockers (tamsulosin) as first-line MET, generally comparable to or better than alternatives like tadalafil (Belkovsky et al. 2023, IBJU; Sun et al. 2024, Front Pharmacol).
• Deflazacort (steroid) as an adjunct reduces ureteric mucosal edema, which can further aid passage - a reasonably common Indian-practice combination (branded "Urimax-Z" not "Vrimax-Z" as transcribed).
• PPI (pantoprazole) covers gastric mucosal protection during antibiotic/analgesic use.
• Oxybutynin manages irritative bladder symptoms as the stone migrates distally.

Investigations in This Case - Explained

1. Chest X-ray and ECG - Pre-operative/pre-procedure work-up

2. USG (Ultrasound, KUB)

• Reliably shows dilatation of the renal pelvis and calyces (hydronephrosis) and a dilated ureter (hydroureter) when the system is obstructed.
• Can detect stones in the kidney or the very proximal/distal ureter as echogenic foci with posterior acoustic shadowing.
• Its major limitation: the mid-ureter is often obscured by overlying bowel gas, so it frequently cannot directly visualize a mid-ureteric stone - it infers obstruction indirectly from the hydronephrosis/hydroureter, which is exactly what happened here (the stone itself was localized on CT, not USG). Ultrasound is preferred first-line in pregnant patients or when clinical suspicion is low, since it avoids radiation - Bailey and Love's Short Practice of Surgery, p. 714.

3. CT Abdomen (CT KUB - non-contrast)

• Performed as a low-dose, non-contrast CT from the kidneys down to the pubic symphysis (no IV or oral contrast needed - contrast doesn't help stone detection and can even mask small stones).
• Stones appear as high-attenuation (calcific) foci; the scan also shows secondary signs of obstruction: hydronephrosis, hydroureter, renal enlargement, and perinephric fat stranding.
• Stones most commonly lodge at the three anatomic narrowings of the ureter: pelviureteric junction (PUJ), pelvic brim (where the ureter crosses the iliac vessels), and the vesicoureteric junction (VUJ) - in this patient, the stone was at the lower ureter, consistent with impaction near the VUJ, a common site for stones to cause colicky pain radiating to the groin/scrotum (T11-L2 referred pain pattern) - Grainger & Allison's Diagnostic Radiology; Gray's Anatomy for Students, p. 4162-4167; Bailey and Love's Short Practice of Surgery, p. 716-730.
• CT also has the advantage of excluding alternative causes of acute abdominal/flank pain in one scan, which ultrasound cannot reliably do.

Why both USG and CT were used together

T-OTROPAN (Oxybutynin) - 2.5mg, 1-0-1

What it is

Mechanism

• Increases bladder capacity
• Reduces involuntary detrusor contractions/spasms
• Decreases urinary urgency, frequency, and urge incontinence

Why it was prescribed in this case

• Urgency, frequency, dysuria
• Bladder spasm-type discomfort (sometimes felt as suprapubic pain in addition to loin pain)

Key safety points

• Contraindicated in urinary retention, bladder outlet obstruction, uncontrolled narrow-angle glaucoma, and significant GI obstruction/dysmotility.
• Common side effects: dry mouth, constipation, drowsiness, dizziness, blurred vision (typical anticholinergic effects).
• Rare but serious: angioedema of face/lips/tongue/larynx - requires immediate discontinuation.

Pharmacist Intervention in This Case: Mr. Bharath, Right Ureteric Calculus with Hydroureteronephrosis

1. Renal function-based dosing of Amikacin (highest-priority issue)

• Amikacin is an aminoglycoside, cleared renally, and is well documented to cause nephrotoxicity and ototoxicity, with acute kidney injury typically appearing 5-10 days after initiation and presenting as nonoliguric AKI with reduced urine-concentrating ability - Comprehensive Clinical Nephrology, 7th Ed.
• Intervention: Confirm baseline serum creatinine/eGFR before the first dose, dose amikacin by actual/ideal body weight (750mg in a 52.3kg patient works out to ~14.3mg/kg, at the higher end of extended-interval dosing - verify this is intentional and not simply a round-number order), and monitor renal function and trough levels if therapy extends beyond 3 days, since peak concentration correlates with efficacy but rising trough correlates with toxicity risk - Katzung's Basic and Clinical Pharmacology, 16th Ed.
• Intervention: Question whether double gram-negative coverage (Amikacin + Cefoperazone-Sulbactam) is still needed once urine culture and sensitivity results are available, and de-escalate/stop the aminoglycoside as early as clinically safe to limit nephrotoxic exposure in an already obstructed kidney - Campbell-Walsh-Wein Urology.

2. Duplicate PPI therapy (IV-to-oral overlap)

• Intervention: This is a therapeutic duplication - a pharmacist should reconcile the chart and ensure only one route/formulation of pantoprazole is active at a time (switch IV to oral once the patient tolerates oral intake, not add both).

3. Antibiotic de-escalation and duration check

• IV Cefoperazone-Sulbactam (Folbact) 1.5g TID + Amikacin was appropriately stepped down to oral Augmentin (Amoxicillin-Clavulanate) 625mg BD for 7 days at discharge - a pharmacist should confirm this de-escalation was culture-guided (empirical broad cover during the febrile/obstructed phase, narrowed once sensitivity is known) rather than default, and verify the total antibiotic duration (IV days + 7 oral days) isn't excessive for an uncomplicated stone-associated UTI.
• Intervention: Verify penicillin/cephalosporin allergy history before Augmentin and cefoperazone-sulbactam, since cross-reactivity between penicillins and cephalosporins exists.

4. Analgesia gap

• Intervention: A pharmacist should query the prescriber to confirm adequate analgesic coverage was ordered and clearly documented, since NSAIDs are actually preferred over opioids in renal colic (they reduce ureteric smooth muscle spasm and inflammation, not just pain perception) - and should also check renal function before any NSAID given the obstructive picture, since NSAIDs can worsen renal perfusion in obstructed/compromised kidneys.

5. Tamsulosin + Deflazacort (Urimax-Z) counseling points

• Tamsulosin (alpha-1A blocker): risk of first-dose orthostatic hypotension/dizziness - counsel to take at the same time each day (after the same meal), rise slowly from sitting/lying, and avoid concurrent PDE5-inhibitors (e.g., sildenafil) which compound the hypotensive effect.
• Deflazacort (corticosteroid component): even a short course can raise blood glucose and cause GI upset.
  • Intervention: Screen for diabetes/glucose intolerance before starting, advise taking with food, and confirm the steroid is tapered/stopped appropriately (not left as an open-ended prescription) since it's meant only as a short adjunct to reduce ureteric edema.

6. Oxybutynin (Ditropan/Otropan) safety check

• Anticholinergic - contraindicated in urinary retention, bladder outlet obstruction, and uncontrolled narrow-angle glaucoma.
• Intervention: Confirm the patient has no bladder outlet obstruction (he doesn't - his obstruction is ureteric, not at the bladder neck) and counsel on dry mouth, constipation, drowsiness, and blurred vision; advise caution with driving until effects are known, and avoid combining with alcohol or other sedating anticholinergics (additive effect with any pre-op sedative premedication given).

7. Ondansetron (Emeset) - QT monitoring

• Ondansetron carries a dose-dependent QT-prolongation risk.
• Intervention: Not a major concern for a single short course in a young patient with a normal ECG (NSR was documented), but worth noting if any other QT-prolonging agents are added later.

8. Tetanus toxoid (TT) justification

• Intervention: Verify indication and prior immunization history before administering TT - it's not routinely required for a ureteric stone admission unless tied to a specific wound/procedure or a lapsed immunization schedule. If given "just in case" pre-operatively, confirm it was a deliberate protocol decision.

9. Discharge/counseling and stone-recurrence prevention

• Counsel on high fluid intake (2.5-3 L/day) to keep urine output high and dilute, which is the single most evidence-based measure to prevent stone recurrence.
• Advise moderate dietary sodium and animal-protein restriction, adequate (not restricted) dietary calcium, and reduced oxalate-rich foods, pending stone composition analysis if the stone is retrieved/passed.
• Recommend metabolic work-up (24-hour urine chemistry, serum calcium/uric acid) at follow-up, since recurrent stone formers benefit from targeted pharmacologic prevention (e.g., thiazides for hypercalciuria, allopurinol for hyperuricosuria, citrate for hypocitraturia) - this reflects the classic Pak protocol for selective medical management of nephrolithiasis.
• Confirm patient understands the discharge regimen sequence: Augmentin and Pan are twice/once daily for 7 days, while Urimax and Otropan continue at 0-0-1/1-0-1 - clear counseling reduces the risk of missed doses or accidental double-dosing of similarly named agents (Pan vs Urimax vs Otropan can be easily confused by a lay patient).

Overall assessment

Patient Counseling Points for Mr. Bharath (Right Ureteric Stone with Hydroureteronephrosis)

1. Understanding his condition

2. Medication counseling (discharge drugs, 7-day course)

• Take medicines exactly as timed (1-0-1 = morning and night; 0-0-1 = night only) - don't double up if a dose is missed, just take the next one on time.
• No alcohol while on Augmentin and Oxybutynin (increases drowsiness/GI upset).
• Do not stop Urimax or Otropan on his own even if pain improves - finish the course as prescribed by the urologist.

3. Fluid intake - the single most important instruction

• Drink at least 2.5-3 liters (10-12 glasses) of water a day, spread through the day, not all at once. This is the most effective thing he can do to help the remaining stone fragment pass and to prevent new stones from forming.
• Urine should look pale/clear, not dark yellow - use that as his own visual check.

4. Diet advice to prevent recurrence

• Reduce salt (sodium) intake - excess salt increases calcium in urine, which promotes stone formation.
• Don't overly restrict dietary calcium (dairy) - normal calcium intake is fine and actually protective; it's excess salt/animal protein/oxalate that matters more.
• Cut down on foods high in oxalate if advised after stone composition is known (e.g., spinach, nuts, chocolate, tea) - this can be refined once the stone type is confirmed.
• Limit red meat and animal protein excess, and avoid carbonated/cola drinks.

5. Warning signs - when to come back immediately

• Fever, chills, or shivering
• Worsening or unbearable flank/groin pain
• Persistent vomiting, unable to keep fluids down
• Reduced urine output or inability to pass urine
• Blood in urine that is heavy/persistent (not just pink-tinged)
• Any allergic reaction - rash, facial/lip swelling, difficulty breathing (especially after Augmentin)

6. Activity and follow-up

• He can resume normal light activity but should avoid heavy strain/exercise until reviewed by the urologist.
• Strain urine if possible (pass through a fine sieve/cloth) to catch any stone fragment that passes - bring it to follow-up for stone composition analysis, which helps guide future prevention.
• Keep the follow-up appointment with urology - likely for a repeat ultrasound/CT to confirm the stone has passed or to plan further intervention (lithotripsy/ureteroscopy) if it hasn't.
• Long-term: since he's only 26, ask his doctor about a metabolic work-up (blood and 24-hour urine tests) to check for an underlying cause of stone formation and prevent recurrence, since first stones at a young age carry a higher lifetime recurrence risk.

7. Simple takeaway summary for the patient